Pulmonary tuberculosis
Conditions
Interventions
Experimental group:N-acetylcysteine as an add-on to antituberculosis chemotherapy
Control group:Antituberculosis chemotherapy
Sponsors
Henan Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subject age: >= 18 years, , male or female; 2. Pulmonary tuberculosis patients confirmed by two positive sputum smear results or positive sputum cultures or positive results of Xpert; 3. Sensitivity to rifampicin (confirmed by DST and/or Xpert); 4. Active lesions in the lungs, with or without cavitation, confirmed on chest x-ray; 5. Absence of hemoptysis; 6. Normal liver function prior to treatment (ALT, AST, T-BiL all within normal limits); 7. Absence of chronic respiratory disease (COPD, asthma, etc.); 8. Absence of chronic liver or kidney disease (viral hepatitis, liver tuberculosis, nephritis, etc.); 9. Absence of mental illness or epilepsy; 10. Absence of immunocompromised and immunosuppressive drugs within the last 3 months; 11. Fully understand the purpose and requirements of this test and voluntarily sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients taking other hepatotoxic drugs (overdose of acetaminophen, etc.); 2. Patients with non-tuberculous mycobacteria (NTM) infections; 3. HIV positive patient; 4. Patients with concomitant malignancies; 5. Patients who do not take their medication regularly as planned or who do not complete their course of treatment; 6. Patients who forced discontinuation due to allergy or adverse reactions (hepatic impairment, etc.); 7. Lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative conversion rate of bacteria;QB-Spot;Radiological indicators (X-ray, CT);Body immune state;Treatment failure condition;Recurrent condition;Acquired drug resistance (ADR) situation;Drug induced liver injury (DILI);Liver function index; | — |
Countries
China
Contacts
Public ContactHu Xu
Henan Chest Hospital
Outcome results
None listed